WILLIAM WELSH: Open Payments
NPI 1568401255 · WHITTIER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,548 in 68 payments from 19 companies in 2025. Trend: 2023 $1,714 · 2024 $1,616 · 2025 $1,548
Food & beverage: $1,548
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $196 |
| Lilly USA, LLC | 6 | $141 |
| Otsuka America Pharmaceutical, Inc. | 6 | $131 |
| Amgen Inc. | 6 | $128 |
| PFIZER INC. | 5 | $120 |
| GlaxoSmithKline, LLC. | 6 | $115 |
| Sumitomo Pharma America, Inc. | 4 | $114 |
| Neurocrine BioSciences, Inc. | 4 | $104 |
| Novartis Pharmaceuticals Corporation | 3 | $77 |
| Novo Nordisk Inc | 4 | $69 |
Products named: REXULTI, GEMTESA, INGREZZA, NURTEC ODT, JARDIANCE, OTEZLA, FARXIGA, AIRSUPRA.
Industry payments across CA — which companies pay providers there.
